常染色体隐性高胆固醇血症的长期心血管结局
该研究收集52例常染色体隐性高胆固醇血症(ARH)患者数据,基线LDL-C为571.9±171.7 mg/dl。平均随访14.1±7.3年,尽管强化降脂治疗,LDL-C最低点均值为164.0±85.1 mg/dl,仅23.1%达到<100 mg/dl。随访期间26.9%发生动脉粥样硬化性心血管疾病(ASCVD),11.5%新诊断主动脉瓣狭窄。
要点
- ARH患者基线LDL-C极高,强化治疗后仅23.1%达到LDL-C<100 mg/dl。
- 随访期间26.9%发生ASCVD,11.5%新发主动脉瓣狭窄,无卒中发生。
- 诊断时年龄≥30岁和存在冠心病是发生ASCVD的主要预测因素。
核心结论
- 尽管强化治疗,ARH患者LDL-C仍远未达标,长期心血管预后差。
- 早期诊断和治疗至关重要,ARH的有效治疗方案仍缺乏。
研究设计与样本
- 通过电子检索识别已发表的ARH病例,并向通讯作者和治疗医生收集标准化随访信息。
- 共纳入52例患者(女性28例,男性24例),年龄31.1±17.1岁,基线LDL-C为571.9±171.7 mg/dl。
- 平均随访14.1±7.3年。
主要发现
- 随访期间高强度他汀和依折麦布联合脂蛋白血浆置换的使用显著增加,6例加用洛美他派。
- LDL-C最低点均值为164.0±85.1 mg/dl(较基线降低69.6%),使用洛美他派者降幅更大(-88.3%)。
- 23.1%的患者达到LDL-C<100 mg/dl。
- 随访期间26.9%发生ASCVD,11.5%新诊断主动脉瓣狭窄,年绝对风险分别为1.9%和0.8%。
- 未观察到卒中发生;年龄≥30岁和诊断时存在冠心病是发生ASCVD的主要预测因素。
关键数值与推荐
- LDL-C达标定义为<100 mg/dl,23.1%的ARH患者达到此目标。
- LDL-C最低点均值164.0±85.1 mg/dl,较基线降低69.6%;使用洛美他派者降低88.3%。
- ASCVD年绝对风险1.9%,主动脉瓣狭窄年绝对风险0.8%。
临床怎么用
- 对ARH患者应尽早诊断并启动强化降脂治疗,包括高强度他汀、依折麦布和脂蛋白血浆置换。
- 洛美他派可进一步降低LDL-C,但需关注其可及性和安全性。
- 需密切监测ASCVD和主动脉瓣狭窄的发生,尤其对年龄≥30岁或诊断时已有冠心病的患者。
局限性
- ARH为罕见病,样本量仅52例,可能限制统计效能和普遍性。
- 数据来源于已发表病例和医生回顾性提供的信息,可能存在选择偏倚和信息不完整。
- 随访时间平均14.1年,但未报告失访情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal recessive hypercholesterolemia (ARH) is a rare lipid disorder characterized by premature atherosclerotic cardiovascular disease (ASCVD). There are sparse data for clinical management and cardiovascular outcomes in ARH. OBJECTIVES: Evaluation of changes in lipid management, achievement of low-density lipoprotein cholesterol (LDL-C) goals and cardiovascular outcomes in ARH. METHODS: Published ARH cases were identified by electronic search. All corresponding authors and physicians known to treat these patients were asked to provide follow-up information, using a standardized protocol. RESULTS: We collected data for 52 patients (28 females, 24 males; 31.1 ± 17.1 years of age; baseline LDL-C: 571.9 ± 171.7 mg/dl). During a mean follow-up of 14.1 ± 7.3 years, there was a significant increase in the use of high-intensity statin and ezetimibe in combination with lipoprotein apheresis; in 6 patients, lomitapide was also added. Mean LDL-C achieved at nadir was 164.0 ± 85.1 mg/dl (-69.6% from baseline), with a better response in patients taking lomitapide (-88.3%). Overall, 23.1% of ARH patients reached LDL-C of <100 mg/dl. During follow-up, 26.9% of patients had incident ASCVD, and 11.5% had a new diagnosis of aortic valve stenosis (absolute risk per year of 1.9% and 0.8%, respectively). No incident stroke was observed. Age (≥30 years) and the presence of coronary artery disease at diagnosis were the major predictors of incident ASCVD. CONCLUSIONS: Despite intensive treatment, LDL-C in ARH patients remains far from targets, and this translates into a poor long-term cardiovascular prognosis. Our data highlight the importance of an early diagnosis and treatment and confirm the fact that an effective treatment protocol for ARH is still lacking.
引用
- D'Erasmo L, Minicocci I, Nicolucci A, et al. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. J Am Coll Cardiol. 2018. PMID: 29348020. doi:10.1016/j.jacc.2017.11.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。